Endogenous hallucinogens as ligands of the trace amine receptors: A possible role in sensory perception
This theory-building paper (2009) proposes that endogenous hallucinogen trace amine receptors (not serotonin 2A receptors) mediate the visual altering effects of psychedelics.
Abstract
While the endogenous hallucinogens, N,N-dimethyltryptamine, 5-hydroxy-N,N-dimethyl-tryptamine and 5-methoxy-N,N-dimethyltryptamine, have been acknowledged as naturally occurring components of the mammalian body for decades, their biological function remains as elusive now as it was at the time of their discovery. The recent discovery of the trace amine associated receptors and the activity of DMT and other hallucinogenic compounds at these receptor sites leads to the hypothesis that the endogenous hallucinogens act as neurotransmitters of a subclass of these trace amine receptors. Additionally, while activity at the serotonin 5-HT2A receptor has been proposed as being responsible for the hallucinogenic affects of administered hallucinogens, in their natural setting the 5-HT2A receptor may not interact with the endogenous hallucinogens at all. Additionally 5-HT2A agonist activity is unable to account for the visual altering effects of many of the administered hallucinogens; these effects may be mediated by one of the endogenous hallucinogen trace amine receptors rather than the serotonin 5-HT2A receptor. Therefore, activity at the trace amine receptors, in addition to serotonin receptors, may play a large role in the sensory altering effects of administered hallucinogens and the trace amine receptors along with their endogenous hallucinogen ligands may serve an endogenous role in mediating sensory perception in the mammalian central nervous system. Thus the theory proposed states that these compounds act as true endogenous hallucinogenic transmitters acting in regions of the central nervous system involved in sensory perception.
Research Summary of 'Endogenous hallucinogens as ligands of the trace amine receptors: A possible role in sensory perception'
Introduction
N,N-dimethyltryptamine (DMT), 5-hydroxy-N,N-dimethyltryptamine (bufotenine) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) are established endogenous constituents of human blood, brain and cerebrospinal fluid, yet their biological function remains unclear. Wallach frames this uncertainty against the 2001 discovery of the trace amine associated receptor (TAAR) family and reports that several hallucinogens, including DMT, show activity at TAAR sites. TAARs are expressed in many central nervous system (CNS) regions implicated in sensory processing (prefrontal cortex, hippocampus, substantia nigra, amygdala, basal ganglia), and nine TAAR genes have been identified in humans, suggesting a plausible physiological ligand–receptor relationship with the endogenous tryptamines. The paper proposes a hypothesis rather than reporting new experimental data: that endogenous hallucinogens function as bona fide neurotransmitters for a subclass of TAARs and thereby contribute to sensory perception. Wallach argues that, although many hallucinogens interact with serotonin receptors (notably 5-HT2A), serotonin activity alone cannot account for the pattern of sensory effects—particularly visual phenomena—observed with different compounds. The core aim is to synthesise pharmacological, genetic and behavioural evidence to support a model in which TAAR-mediated signalling by endogenous hallucinogens plays an endogenous role in generating and regulating ordinary sensory experience, and when dysregulated may underlie altered states of consciousness (ASC) and psychosis.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Compound
- Topic
- APA Citation
Wallach, J. (2009). Endogenous hallucinogens as ligands of the trace amine receptors: A possible role in sensory perception. Medical Hypotheses, 72(1), 91-94. https://doi.org/10.1016/j.mehy.2008.07.052
References (3)
Papers cited by this study that are also in Blossom
Jacob, M. S., Presti, D. E. · Medical Hypotheses (2005)
Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Cited By (10)
Papers in Blossom that reference this study
Ermakova, A. O., Dunbar, F., Rucker, J. et al. · Journal of Psychopharmacology (2021)
Barker, S. · Frontiers in Neuroscience (2018)
De Gregorio, D., Posa, L., Ochoa-Sanchez, R. et al. · Pharmacological Research (2016)
Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)
Frecska, E., Bokor, P., Winkelman, M. J. · Frontiers in Pharmacology (2016)
Schenberg, E. E., Alexandre, J. F. M., Filev, R. et al. · PLOS ONE (2015)
Szabo, A. · Frontiers in Immunology (2015)
Szabo, A., Kovacs, A., Frecska, E. et al. · PLOS ONE (2014)
Frecska, E., Szabo, A., Winkelman, M. J. et al. · Translational Neurosciences (2013)
Shen, H. W., Jiang, X. L., Winter, J. C. et al. · Current Drug Metabolism (2010)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.